anti-SARS-CoV-2 COVID 19 Spike RBD Coronavirus Monoclonal Antibody | anti-COVID-19 antibody

Anti-SARS-CoV-2 S-RBD / COVID-19, mouse monoclonal antibody (Detection Ab)

CATALOG #	HOST	REACTIVITY	APPLICATIONS
AAA59160	**Mouse ascites**	**SARS-CoV-2**	**ELISA, Lateral Flow**

PRODUCT SYNONYMS

COVID 19 Spike RBD Coronavirus; Monoclonal Antibody; Anti-SARS-CoV-2 S-RBD / COVID-19; mouse monoclonal antibody (Detection Ab); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike RBD; Receptor Binding Domain; anti-COVID-19 antibody

PRODUCT SPECIFICATIONS

Host	Mouse ascites
Reactivity	SARS-CoV-2
Clonality	Monoclonal
Isotype	Mouse IgG1
Clone Number	17F11
Purity/Purification	Purity: >95% by HPLC & SDS-PAGE Purification: Protein A purified
Form/Format	Liquid; supplied in 0.01 M PBS without preservative.
Applicable Applications for anti-COVID-19 antibody	ELISA, LF (Lateral Flow)
Immunogen	Recombinant SARS-CoV-2 S-RBD protein.
Dry Ice Note	The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
Preparation and Storage	Aliquot and store at -20 degree C for long term. Avoid repeated freeze and thaw cycles.

ADDITIONAL INFORMATION

Related Product Information for anti-COVID-19 antibody	The 2019 novel coronavirus, abbreviated as 2019-ncov, is a new strain of coronavirus discovered in the human body in 2019. The symptoms of the virus are fever, fatigue, dry cough, and progressive dyspnea. In severe cases, the symptoms are acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulation dysfunction that can't be corrected. The virus has been confirmed to exist the phenomenon of human-to-human transmission, the shortest incubation period of the virus is only 1 day, and the longest incubation period is 14 days. The patients in incubation period is contagious and there is no specific treatment for the disease. . After a human is infected with a new virus for the first time, the body's immune system will immune-defend the virus and produce specific antibodies. Generally, IgM antibody will appear in 1-2 weeks and IgG antibody will appear in 4 weeks.
References	1. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance. 2. "Pneumonia diagnosis and treatment program for novel coronavirus infection" of the National Health Commission of People's Republic of China (Trial Version 3). 3. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: https://stage.aaabiotech.com/monoclonal/covid-19-spike-rbd-coronavirus-antibody-clone-17f11-lateral-flow-elisa/59160